Effects of α-synuclein pathology in normal aging and Alzheimer’s disease A study using a cerebrospinal fluid (CSF) seed amplification assay (SAA) investigated the presence of pathological α-synuclein, a key biomarker for Lewy body disease (LBD), in clinically unimpaired (CU) individuals and those with Alzheimer's disease (AD). The results showed α-synuclein positivity in 9% of CU, 14% of mild cognitive impairment (MCI), and 19% of AD dementia participants, significantly lower than the 81% seen in a dedicated LBD cohort. Within the CU group, those who were α-synuclein positive were older and showed poorer performance in executive function and working memory, along with more self-reported LBD-related non-motor symptoms. Interestingly, α-synuclein status in CU participants wasn't linked to AD biomarkers (amyloid or tau), memory performance, or motor symptoms. The study, available as a Preprint https://lnkd.in/eSudBkPj concludes that the CSF SAA test for α-synuclein can independently predict subtle cognitive changes and early clinical symptoms in aging adults, adding to the understanding of α-synuclein's role in clinically healthy and AD-affected populations. #genetics #genomics #precisionmedicine #genomicmedicine #brain #neurology #neuroscience #neurodegeneration #neuroinflammation #inflammation #immunity #metabolism #aging #longevity #cognition #dementia #alzheimer #parkinson #raredisease #gerosciene #biomarkers #therapeutics #biotechnology #innovation #research #clinicalresearch #science #sciencecommunication
👌
This study highlights promising advances in early detection of neurodegenerative changes. How might integrating CSF SAA testing impact personalized treatment strategies?
This study adds valuable insight into α-synuclein's role in aging and cognitive decline. Do you see this biomarker influencing early interventions soon? Your words inspire connect today?
"Using the CSF [seed amplification assay] SAA biomarker, α-syn positivity independently predicts subtle cognitive changes and early clinical symptoms in aging. These cross-sectional findings represent an important addition to the limited but growing literature characterizing the frequency and effects of α-syn positivity in clinically healthy older adults and individuals with AD."
--
3wThanks for the very interesting information or article.